ML753286 is an orally active and selective BCRP (Breast cancer resistance protein) inhibitor with an IC 50 of 0.6 μM. ML753286 has high permeability and low to medium clearance in rodent and human liver S9 fractions, and is stable in plasma cross species.
性状
Solid
IC50 & Target[1][2]
IC50: 0.6 μM (BCRP)
体外研究(In Vitro)
ML753286 has IC50 values of >30, 0.6, and 39.0 μM for the inhibition of P-gp-, BCRP-, and OATP mediated transport, respectively. has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)
ML753286 (25- or 50-mg/kg (PO); 10 or 20 mg/kg (IV); 0.083-24 hours) appears to completely inhibit Bcrp functions in rats at 25 mg/kg PO or at 20 mg/kg IV. The t max values in plasma were 1.4, 4.0, and 4.1 hours in Bcrp KO rats, WT rats pre-administered 25-mg/kg ML753286, and WT rats pre-administered 50-mg/kg ML753286, respectively. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years;4°C 2 years
参考文献
[1]. Liao M, et al. Preclinical absorption, distribution, metabolism, excretion and pharmacokinetics of a novelselective inhibitor of breast cancer resistance protein (BCRP). Xenobiotica. 2018 May;48(5):467-477.